Abstract
INTRODUCTION
Trisomy 21, or Down syndrome (DS), predisposes individuals to early-onset Alzheimer’s disease (AD). While monoclonal antibodies (mAbs) targeting amyloid are approved for older AD patients, their efficacy in DS remains unexplored. This study examines amyloid positron emission tomography (PET) positivity (A+), memory function, and clinical status across ages in DS to guide mAb trial designs.
METHODS
Cross-sectional data from the Alzheimer Biomarker Consortium–Down Syndrome (ABC-DS) was analyzed. PET amyloid beta in Centiloids classified amyloid status using various cutoffs. Episodic memory was assessed using the modified Cued Recall Test, and clinical status was determined through consensus processes.
RESULTS
Four hundred nine DS adults (mean age = 44.83 years) were evaluated. A+ rates increased with age, with mean amyloid load rising significantly. Memory decline and cognitive impairment are also correlated with age.
DISCUSSION
These findings emphasize the necessity of tailoring mAb trials for DS, considering age-related AD characteristics.
HIGHLIGHTS
There is rapid increase in prevalence of amyloid beta (Aβ) positron emission tomography (PET) positivity in Down syndrome (DS) after the age of 40 years.
Aβ PET positivity thresholds have significant impact on prevalence rates in DS.
There is a significant lag between Aβ PET positivity and clinical symptom onset in DS.
If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.
This post is Copyright: Sophia Krasny,
Cynthia Yan,
Sigan L. Hartley,
Ben L. Handen,
Julie K. Wisch,
Anna H. Boehrwinkle,
Beau M. Ances,
Michael S. Rafii,
the ABC‐DS consortium | June 28, 2024